Lead Sponsor

Centre Francois Baclesse

Collaborators

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•Patient (e) Age (e) over 18 years
•Kidney cancer metastatic or locally advanced
•Anti-angiogenic or targeted therapy (bevacizumab, sorafenib, sunitinib, temsirolimus, another molecule or developing or having obtained authorization in this indication) may be associated with interferon or combined together
•Proposed treatment in first line or second line
•Brain imaging not finding brain metastases
•Having signed the informed consent of study participation
•The patient may have received prior anti-angiogenic

•Cancer of the kidney other than primitive
•Previous history of cancer other than kidney cancer in complete remission for less than 5 years
•Patients under 18 years
•Patients whose treatment is associated with chemotherapy
•disorders of cognitive functions to existing treatment delivery
•Pathology psychiatric evolutionary
•Refusal of participation
•Patient unable to respond to cognitive tests
•Drug use
•Heavy drinking (WHO criteria)
•History of stroke
•History of head trauma
•Brain metastases known
•MMS below normal compared to existing standards for age and socio-cultural